While CSCR is often self-limiting, meaning that it resolves on its own in many cases, some patients may experience persistent or recurrent episodes that require medical intervention. Understanding the causes, risk factors, natural course, and treatment options for CSCR is crucial in managing the condition effectively.

What is Central Serous Chorioretinopathy?

CSCR is an eye disease that occurs when fluid leaks from the choroid (a layer of blood vessels beneath the retina) into the retinal layers, leading to a serous detachment of the macula. The macula is responsible for central vision, and when affected, patients may experience blurred or distorted vision.

CSCR primarily affects men between the ages of 20 and 50, but it can also occur in women and older individuals. In most cases, the condition resolves within a few months, but some individuals may develop chronic or recurrent CSCR, leading to long-term visual problems.

Causes of CSCR

The exact cause of CSCR is not fully understood, but it is believed to result from increased permeability of the choroidal blood vessels. Several physiological and biochemical factors contribute to the development of CSCR, including:

1. Choroidal hyperpermeability – Increased leakage of fluid from the choroid into the retina.
2. Dysregulation of the retinal pigment epithelium (RPE) – The RPE normally acts as a barrier and pump to remove excess fluid. When it malfunctions, fluid accumulates under the retina.
3. Autonomic dysfunction – An imbalance in the nervous system may contribute to abnormal blood vessel function, increasing the risk of fluid leakage.

Risk Factors for CSCR

Several factors can increase the likelihood of developing CSCR. Understanding these risk factors can help in modifying lifestyle habits to reduce the risk of recurrence.

1. Stress and Corticosteroid Use

Psychological stress: CSCR has been strongly associated with high-stress levels. The body’s response to stress leads to increased production of corticosteroids, which can impact choroidal blood flow and permeability.

Corticosteroid use: Systemic or topical steroids, including nasal sprays, inhalers, skin creams, and injections, can trigger or worsen CSCR by increasing fluid leakage from the choroid.

2. Hormonal Factors

Elevated levels of cortisol and epinephrine, particularly in individuals with a high-stress lifestyle, have been linked to CSCR. Some cases occur during pregnancy due to hormonal changes.

3. Hypertension and Cardiovascular Disease

High blood pressure and cardiovascular conditions can contribute to abnormal blood vessel function in the choroid, increasing susceptibility to CSCR.

4. Type A Personality

Individuals who are highly competitive, ambitious, and work in high-stress environments have been found to be more prone to developing CSCR.

5. Sleep Disturbances and Shift Work

People with irregular sleep patterns, including those who work night shifts or experience chronic sleep deprivation, may have an increased risk of developing CSCR.

6. Medications and Substance Use

Use of medications such as decongestants, erectile dysfunction drugs, and stimulants can increase the risk. Excessive alcohol and caffeine consumption have also been linked to CSCR.

7. Helicobacter Pylori Infection

Some studies suggest a possible association between H. pylori infection (a bacteria affecting the stomach) and CSCR.

8. Genetic Predisposition

There is some evidence that CSCR may have a genetic component, with a higher likelihood of occurrence in individuals with a family history of the condition.

Symptoms of CSCR

1. Blurred or hazy central vision
2. Distorted vision (metamorphopsia), where straight lines appear wavy
3. Dark or gray spots in central vision
4. Reduced contrast sensitivity
5. Difficulty with night vision
6. Micropsia, where objects appear smaller than they are
7. Mild color vision changes

Diagnosis of CSCR

Your ophthalmologist will perform several tests to confirm CSCR, including:

1. Dilated Fundus Examination – To assess retinal changes.

2. Optical Coherence Tomography (OCT) – A non-invasive imaging test that provides cross-sectional images of the retina to detect fluid accumulation.

3. Fluorescein Angiography (FA) – Uses a dye injected into the bloodstream to visualize leaking blood vessels.

4. Indocyanine Green Angiography (ICGA) – Helps in detecting choroidal abnormalities.

Natural History of CSCR

The progression of CSCR varies from patient to patient. Most cases follow one of the three patterns:

1. Acute CSCR (Self-limiting Form)

• The most common form.

• Symptoms develop suddenly and may include blurred vision, central scotoma (dark spot in vision), and distortion (metamorphopsia).

• In 80-90% of cases, fluid resolves within 3-6 months without treatment, and vision returns to near-normal levels.

2. Chronic CSCR

• In some cases, fluid persists for more than 6 months.

• The prolonged presence of fluid leads to damage to the retinal pigment epithelium, causing permanent visual impairment.

3. Recurrent CSCR

• Some individuals experience repeated episodes of CSCR over the years.

• With each recurrence, vision may become progressively worse due to cumulative damage to the macula.

FFA showing smoke stack appearance of dye leakage in active CSCR.

Treatment Options for CSCR

Most cases of acute CSCR resolve spontaneously without treatment. However, if vision does not improve or if CSCR becomes chronic, several treatment options are available:

1. Observation (Watchful Waiting)

Recommended for patients with mild symptoms. Because most cases resolve within 3-6 months, doctors may monitor the condition before considering active treatment.

2. Laser Photocoagulation

Used to seal leaking retinal areas, particularly in cases where the leakage is persistent and pin-point. Only suitable for leaks that are located away from the fovea (the central part of the macula).

3. Photodynamic Therapy (PDT)

Involves injecting a light-sensitive dye (verteporfin) into the bloodstream, followed by laser activation to reduce choroidal hyperpermeability. Particularly effective in chronic and recurrent CSCR.

4. Anti-VEGF Injections

May be used in some cases to reduce choroidal vascular leakage. Drugs like Bevacizumab (Avastin) Ranibizumab (Lucentis) and Aflibercept (Eylea) may be considered.

5. Medications

Oral mineralocorticoid receptor antagonists (e.g., Eplerenone, Spironolactone) have shown potential in reducing fluid accumulation in chronic CSCR. Mifepristone, a glucocorticoid receptor antagonist, has been explored as a treatment. However, randomised controlled trial results did not support use of these medications.

Lifestyle Modifications for CSCR Management

Patients with CSCR can benefit from certain lifestyle adjustments to minimize the risk of recurrence and improve overall eye health.

1. Stress Reduction

• Practice relaxation techniques such as yoga, meditation, and deep breathing.

• Engage in leisure activities to reduce psychological stress.

• Consider counseling or cognitive behavioral therapy (CBT) if stress levels are high.

2. Avoid Corticosteroid Use

• If on steroids for another medical condition, discuss alternative treatments with your doctor.

3. Improve Sleep Hygiene

• Maintain a regular sleep schedule.

• Avoid excessive screen time before bedtime.

• Reduce caffeine intake, especially in the evening.

4. Dietary Changes

• Eat a diet rich in antioxidants (leafy greens, fruits, and nuts).

• Reduce salt intake, as excessive sodium can affect vascular health.

• Consider probiotics if H. pylori infection is suspected.

5. Limit Stimulants

• Reduce alcohol, nicotine, and excessive caffeine consumption.

6. Maintain Cardiovascular Health

• Control blood pressure and cholesterol levels through regular check-ups.

• Engage in moderate exercise such as walking or swimming.

The post Central Serous Chorioretinopathy (CSR) appeared first on Dr Rehman Siddiqui.

Vabysmo (faricimab-svoa) is a medication used to treat certain eye conditions that can lead to vision loss. Administered as an injection directly into the eye by a healthcare professional, it works by targeting specific proteins that cause abnormal blood vessel growth and leakage. This helps improve and maintain your vision.

Which eye conditions does Vabysmo (faricimab) treat?

Vabysmo (faricimab) is prescribed for:

1. Neovascular (Wet) Age-Related Macular Degeneration (AMD): A condition where abnormal blood vessels grow under the retina, leading to vision deterioration.
2. Diabetic Macular Edema (DME): Occurs when high blood sugar levels damage retinal blood vessels, causing fluid buildup and swelling that impair vision.

3. Retinal Vein Occlusion

How does Vabysmo (faricimab) work?

Vabysmo (faricimab) targets and blocks two proteins in the eye:

1. Vascular Endothelial Growth Factor A (VEGF-A): Promotes the growth of abnormal blood vessels.
2. Angiopoietin-2 (Ang-2): Causes blood vessels to become unstable and leaky.

By inhibiting both VEGF-A and Ang-2, the medication reduces abnormal vessel growth and leakage, helping to prevent further vision loss and potentially improving vision.

What makes Vabysmo (faricimab) different from other treatments?

Most other treatments focus only on blocking VEGF-A. Vabysmo (faricimab) is unique because it inhibits both VEGF-A and Ang-2. This dual action provides better control over the underlying causes of certain eye diseases.

What are the benefits of using Vabysmo (faricimab)?

– Improved vision: Many patients notice better vision after starting treatment.
– Fewer injections: Due to its dual mechanism, some patients may require injections less frequently than with other treatments.
– Long-term disease management: By addressing two key proteins, it may offer more effective long-term control of eye conditions.

How is Vabysmo (faricimab) administered?

The medication is given as an injection into the eye:

1. Preparation: Your eye is numbed with drops to reduce discomfort.
2. Injection: A tiny needle delivers the medication into the vitreous, the gel-like substance inside your eye.
3. Aftercare: You might be monitored briefly to ensure there are no immediate side effects.

Will the injection hurt?

Most people experience minimal discomfort. The numbing drops help, but you might feel slight pressure or a brief sting during the injection.

How often will I need injections?

Injection frequency varies:

– Initial phase: More frequent injections to gain control over the condition.
– Maintenance phase: Once stabilized, injections may be scheduled less often.

Your doctor will tailor a treatment plan specific to your needs.

What are the possible side effects?

Common side effects include:

– Eye pain or discomfort: Mild irritation after the injection.
– Floaters: Temporary small spots in your vision.
– Increased eye pressure: Usually temporary and monitored by your doctor.

Serious but rare side effects:

– Infection inside the eye (endophthalmitis): Symptoms include severe pain, redness, or vision changes.
– Retinal detachment: Sudden increase in floaters or flashes of light.

Contact your doctor immediately if you experience severe symptoms.

Can I resume normal activities after the injection?

Yes, but take some precautions:

– Avoid rubbing your eye: Reduces the risk of infection.
– Follow doctor’s instructions: Use prescribed eye drops and attend follow-up appointments.
– Monitor symptoms: Report any unusual changes in vision or discomfort.

How does Vabysmo (faricimab) compare to other anti-VEGF treatments?

Vabysmo (faricimab) offers:

– Dual targeting: Blocks both VEGF-A and Ang-2 for more comprehensive treatment.
– Extended dosing intervals: Some patients may need fewer injections over time.
– Improved outcomes: Studies show significant vision improvements in many patients.

Can Vabysmo (faricimab) cure my eye condition?

While it can significantly improve and manage your condition, it is not a cure. Ongoing treatment and regular monitoring are essential to maintain vision improvements.

What should I expect during treatment?

– Regular appointments: Frequent visits at first, possibly less often later.
– Vision assessments and OCT tests: Your doctor will check your vision and eye health regularly.
– Treatment adjustments: Plans may change based on how you respond.

First Vabysmo (Faricimab-svoa) injection in Pakistan was given by Dr. Rehman Siddiqui in January 2023

How long will I need to continue treatment?

Duration varies by individual. Some may require long-term therapy to maintain vision improvements.

How might my vision change over time with Vabysmo (faricimab)?

Many patients experience:

– Initial improvement: Vision may get better after a few treatments.
– Stabilization: Helps prevent further vision loss.
– Long-term maintenance: Ongoing treatment maintains vision gains.

Are there lifestyle changes that can help my condition?

Yes, consider:

– Healthy diet: Eat leafy greens and foods rich in omega-3 fatty acids.
– Regular exercise: Helps overall health and circulation.
– Quit smoking: Smoking can exacerbate eye conditions.
– Blood sugar control: Crucial for diabetic patients.

The post Vabysmo (Faricimab) for treatment of retinal diseases appeared first on Dr Rehman Siddiqui.

Although Stargardt disease can be challenging, understanding its causes, different types, and current treatments can help patients and their families manage the condition better.

The Genetic Basis of Stargardt Disease

Stargardt disease is caused by mutations in a gene known as ABCA4. Genes are like instructions in our cells that tell our body how to function. The ABCA4 gene provides instructions for making a protein that plays a crucial role in the visual cycle, the process by which light entering the eye is converted into signals that our brain interprets as vision.

When the ABCA4 gene is faulty due to mutations, the protein it produces doesn’t work correctly. This malfunction leads to the buildup of toxic substances in the retina, damaging the light-sensitive cells and leading to vision loss. Stargardt disease is inherited in an autosomal recessive manner, meaning a person must inherit two faulty copies of the ABCA4 gene—one from each parent—to develop the disease.

Common Genes Involved in Stargardt Disease

1. ABCA4:is the primary gene associated with Stargardt disease
2. ELOVL4: This gene is involved in the production of very long-chain fatty acids, which are essential for the normal functioning of the retina. Mutations in the ELOVL4 gene can lead to a type of macular degeneration similar to Stargardt, but this is less common.
3. PROM1: The PROM1 gene helps in maintaining the structure of photoreceptors, the cells in the retina that detect light. Mutations in this gene can cause a variant of macular dystrophy that shares some characteristics with Stargardt disease.

Mutations in the RP1L1 gene can lead to a retinal condition known as occult macular dystrophy, which may mimic the symptoms of Stargardt disease but is usually less severe.

These genes highlight the complexity of retinal diseases, as mutations in different genes can produce similar effects on vision. However, ABCA4 remains the most common and well-understood cause of Stargardt disease.

Subtypes of Stargardt Disease

Stargardt disease is not a one-size-fits-all condition; it can vary significantly from person to person. Researchers have identified several subtypes of the disease, each with unique characteristics and progression patterns. Understanding these subtypes can help in diagnosing the disease and tailoring treatment approaches.

1. Early-Onset Stargardt Disease: This subtype typically begins in childhood, often before the age of 10. It is characterized by rapid progression and severe vision loss. Patients with early-onset Stargardt often have larger and more numerous yellowish-white deposits called “flecks” on the retina. These flecks are a hallmark of the disease and are visible during an eye examination.
2. Late-Onset Stargardt Disease: This form of the disease may not become apparent until adolescence or adulthood. The progression of vision loss is usually slower compared to early-onset Stargardt. Patients may maintain functional vision for a longer period, and the flecks in the retina are often fewer and less pronounced.
3. Foveal-Sparing Stargardt Disease: In this subtype, the central part of the macula (the fovea) is less affected, or “spared,” for a longer time. As a result, patients retain better central vision compared to those with more typical forms of Stargardt. However, peripheral vision may still be affected.
4. Bull’s-Eye Maculopathy: This subtype is named after the bull’s-eye appearance of the retina, where a ring of damaged tissue surrounds a relatively unaffected center. This pattern can sometimes be seen in Stargardt disease and can indicate a specific stage of retinal degeneration.
5. Pattern Dystrophy: In some cases, Stargardt disease may present with a pattern of pigmentation changes in the retina, similar to other retinal dystrophies. This can make diagnosis challenging, as it may overlap with other retinal conditions.

Symptoms and Findings Based on Subtypes

The symptoms of Stargardt disease can vary depending on the subtype, but there are common signs that most patients experience:

1. Central Vision Loss: The most significant and common symptom of Stargardt’s disease is the gradual loss of central vision. This affects the ability to see fine details, read, and recognize faces.
2. Difficulty in Low Light: Many patients with Stargardt disease find it challenging to see in low light or dim environments. This is because the damaged retinal cells are less effective in processing light, especially in conditions where light is limited.
3. Color Vision Changes: Some patients may experience changes in color vision, making it difficult to distinguish between different colors, particularly in the early stages of the disease.
4. Photophobia: Sensitivity to light, or photophobia, is another common symptom. Bright lights may cause discomfort or make it harder to see clearly.
5. Flecks in the Retina: During an eye examination, doctors may observe the presence of yellowish-white flecks in the retina. These are deposits of lipofuscin, a byproduct of the damaged visual cycle, and are a characteristic feature of Stargardt disease.
6. Peripheral Vision Loss: While central vision loss is more common, some subtypes of Stargardt disease can also affect peripheral vision. This can lead to difficulties with navigation and spatial awareness.

Current Treatments for Stargardt Disease

As of now, there is no cure for Stargardt disease, but several treatments and strategies can help manage the condition and improve the quality of life for those affected. These include:

1. Low Vision Aids: Low vision aids, such as magnifying glasses, telescopic lenses, and specialized reading devices, can help patients make the most of their remaining vision. These tools are especially useful for reading, writing, and other close-up tasks.
2. Blue Light Protection: Exposure to blue light, which is emitted by digital screens and sunlight, can worsen the progression of Stargardt disease. Wearing sunglasses with blue light filters or using screen protectors can help reduce exposure and protect the retina.
3. Nutritional Supplements: Some studies suggest that certain nutritional supplements, such as lutein, zeaxanthin, and omega-3 fatty acids, may support retinal health. However, it’s important to consult with an eye specialist before starting any supplement regimen.
4. Gene Therapy: Gene therapy is an emerging treatment option that aims to correct the underlying genetic mutation in Stargardt disease. While still in experimental stages, clinical trials are ongoing, and early results are promising. Gene therapy involves delivering a healthy copy of the ABCA4 gene to the retina to restore its normal function.
5. Stem Cell Therapy: Another area of research is stem cell therapy, which involves replacing damaged retinal cells with healthy ones derived from stem cells. This treatment is still under investigation, but it holds potential for restoring vision in patients with Stargardt disease.
6. Pharmacological Therapies: Researchers are also exploring the use of drugs that can slow down or halt the progression of Stargardt disease. These drugs work by reducing the buildup of toxic substances in the retina or by protecting retinal cells from further damage.
7. Clinical Trials: Participating in clinical trials can provide patients with access to cutting-edge treatments that are not yet widely available. It also contributes to the advancement of research in finding a cure for Stargardt disease.

Unfortunately, the promise of stem cell therapy for retinal dystrophies has led to a surge in fraudulent clinics and treatments. These scams prey on the desperation of patients and their families, offering false hope and draining financial resources.

Do’s and Don’ts for Managing Stargardt Disease

Living with Stargardt disease can be challenging, but following certain guidelines can help manage the condition and maintain quality of life:

Do’s:

1. Regular Eye Exams: Regular check-ups with an eye specialist are crucial for monitoring the progression of Stargardt disease and adjusting treatment as needed.

2. Use Low Vision Aids: Make use of low vision aids to help with daily activities. These devices can enhance your ability to perform tasks that require detailed vision.

3. Protect Your Eyes from Sunlight: Wear sunglasses with UV and blue light protection when outdoors. This can help prevent further retinal damage.

4. Adopt a Healthy Diet: A diet rich in fruits, vegetables, and omega-3 fatty acids can support overall eye health. Foods high in lutein and zeaxanthin, such as leafy greens and eggs, are particularly beneficial.

5. Stay Informed: Keep up-to-date with the latest research and treatment options for Stargardt disease. This knowledge can empower you to make informed decisions about your care.

Don’ts

Avoid Smoking: Smoking can exacerbate the progression of Stargardt disease by increasing oxidative stress on the retina. If you smoke, seek help to quit.

Limit Sunlight Exposure: Prolonged exposure to sunlight damages already diseased retina in patients with Stargardt disease. We recommend using UV filter sunglasses, wear hats and avoid being outside in the open during peak sunlight hours (9am to 5pm in Pakistan).

The post Stargardt Disease- ABCA4 Retinopathy appeared first on Dr Rehman Siddiqui.

A photograph of Optos advanced retinal imaging system at RETINA & EYE ASSOCIATES, DHA, Karachi.

A Clear View of the Retina

The retina, a delicate tissue lining the back of the eye, plays a crucial role in vision. Any abnormalities in the retina can lead to vision impairment or loss if not promptly addressed. The Optos California device provides an unparalleled view of the entire retina, including the peripheral areas which are often challenging to visualize with traditional methods. This wide-field imaging capability enables eye care professionals to detect retinal diseases at their earliest stages, facilitating timely intervention and preventing complications.

Detecting Retinal Tears and Detachment

Retinal tears and detachment are serious conditions that require prompt attention to prevent permanent vision loss. With the Optos California device, eye care specialists can accurately identify even the smallest retinal tears or detachments, particularly in the periphery, thanks to its high-resolution imaging capabilities. By detecting these issues early on, treatment options such as laser therapy or surgical repair can be initiated promptly, increasing the likelihood of preserving vision and preventing further damage to the retina.

Managing Diabetic Retinopathy

Diabetic retinopathy is a common complication of diabetes and a leading cause of vision loss worldwide. Regular eye screenings are essential for individuals with diabetes to detect diabetic retinopathy in its early stages when treatment is most effective. The Optos California device excels in diabetic retinopathy screening by providing wider and detailed images of the retina, allowing doctors to monitor changes over time and intervene as needed to prevent vision loss. Its non-invasive nature and ability to capture high-quality images quickly make it an invaluable tool in managing diabetic eye disease.

.

Advantages of the Optos California Device

1. Non-invasive Imaging: The Optos California device offers a non-invasive imaging solution, eliminating the need for uncomfortable procedures and minimizing patient discomfort.
2. Rapid Image Acquisition: With its swift image capture capabilities, the Optos California device streamlines the diagnostic process, reducing wait times and enabling prompt evaluation by eye care specialists.
3. Comprehensive Retinal Coverage: Unlike traditional imaging methods that may only capture a portion of the retina, the Optos California device provides a panoramic view, ensuring no abnormalities go unnoticed.
4. Early Disease Detection: By detecting retinal diseases in their early stages, the Optos California device empowers healthcare professionals to implement timely interventions and prevent vision loss.
5. Patient Education: The device’s detailed imaging capabilities allow healthcare providers to educate patients about their retinal health, fostering greater awareness and promoting proactive eye care habits.

To book the test call 0306-2319393

The post OPTOS Ultra wide field (UWF) Retinal Imaging appeared first on Dr Rehman Siddiqui.

One of the treatments for this condition is the scleral buckle procedure. This blogs aims to shed light on what the scleral buckle procedure entails, when it is advised, the risks associated with it, and the expectations for recovery post-surgery. The objective is to provide easily digestible information to facilitate well-informed decisions regarding eye health.

Indications for Scleral Buckle Surgery

When faced with retinal detachment, time is of the essence. The longer the retina remains detached, the greater the risk of irreversible vision loss. Scleral buckle surgery is generally indicated under the following conditions:

1. Significant Detachment
If a large part of the retina is detached and poses an imminent risk to vision.

2. Failed Previous Treatment
In cases where other less invasive treatments like laser therapy or pneumatic retinopexy have failed to resolve the detachment.

3. Presence of Symptoms
Noticeable symptoms like a sudden flurry of floaters, bright flashes, or a dark curtain over the field of vision often suggest the necessity for surgical intervention.

4. Detachment Complexity
The complexity and location of the detachment may necessitate the use of scleral buckle over other treatments.

What is Scleral Buckle Surgery?

In simple terms, scleral buckle surgery involves attaching a flexible band (the ‘buckle’) around the white of the eye, called the sclera. This band pushes the sclera toward the detached retina, allowing the retina to settle back into its proper position. Sometimes, a freezing probe is also used to secure the retina to the eye wall. The buckle remains in place permanently to prevent future detachments.

Risks of Scleral Buckle Surgery

No surgical procedure is devoid of risks, and scleral buckle surgery is no exception. Some of the risks you should be aware of are:

1. Infection
Although uncommon, there’s a possibility of infection post-surgery which might require additional treatment.

2. Glaucoma
Increased pressure within the eye, known as glaucoma, can develop as a result of the surgery.

3. Double Vision
Some patients may experience temporary or even permanent double vision.

4. Refractive Changes
The surgery may induce changes in the eye’s natural focus, necessitating the use of new eyeglasses.

5. Redetachment
Though rare, there’s a risk that the retina may detach again, requiring further surgical intervention.

6. Ocular Pain
Some patients experience mild to moderate discomfort or pain after the surgery.

It is crucial to discuss all possible risks and complications with your eye specialist to make an informed decision.

Post-Operative Outcomes

1. Vision Restoration
Many patients experience a substantial improvement in vision post-surgery, although complete restoration cannot always be guaranteed.

2. Recovery Time
Patients can expect a recovery period ranging from a few weeks to a couple of months, during which certain activities might be restricted.

3. Follow-up Appointments
Regular follow-up appointments are crucial to monitor healing and to detect any potential complications at the earliest.

4. Lifestyle Modifications
Temporary lifestyle modifications, like avoiding strenuous activities and sleeping in a specific position, may be advised.

Conclusion

Retinal detachment is a serious condition that demands immediate action. Scleral buckle surgery stands as a time-tested method for treating significant and complex cases of retinal detachment. However, it is imperative to weigh the potential benefits against the possible risks and discuss in-depth with your eye specialist.

Remember, preserving your vision is not just a matter of good fortune; it’s a result of taking timely, informed actions.

The post Scleral Buckling Surgery for Retinal Detachment appeared first on Dr Rehman Siddiqui.

Diabetic Macular Edema is a medical condition that can occur in people who have diabetes. In this condition, fluid builds up in a specific part of your eye called the “macula.” The macula is vital for our sharp vision, which we use for reading, driving, and recognizing faces. When fluid accumulates in this area, it can cause your vision to become blurry or wavy.

Why is it important? 

The onset of DME can significantly reduce the quality of life. Activities that require keen vision like reading, driving, or even navigating through your home become challenging. If not managed properly, it can lead to permanent vision loss.

What Causes DME?

The main culprit behind DME is diabetes—both Type 1 and Type 2. In diabetes, high blood sugar levels can damage the small blood vessels in your eyes. These damaged vessels can leak fluid into the retina, leading to DME.

Risk Factors

– Poorly Managed Diabetes: If your blood sugar levels are not well-controlled, your risk increases.

– Duration of Diabetes: The longer you’ve had diabetes, the higher the risk.

– High Blood Pressure: This can exacerbate the problem.

– High Cholesterol Levels: Like high blood pressure, high cholesterol can also aggravate DME.

How is DME Diagnosed?

Early detection is crucial for effectively managing DME. Regular eye examinations are essential, especially if you have diabetes. Some of the diagnostic tests may include:

– Visual Acuity Test: A standard eye chart test that measures your vision.

– Dilated Eye Exam: Drops are placed in your eyes to widen, or dilate, the pupils, allowing the doctor to see more of the inside of your eyes.

– Optical Coherence Tomography (OCT): A non-invasive imaging test that takes detailed cross-sectional pictures of the retina.

OCT scan of extensive diabetic macular edema

FFA showing diabetic macular edema

Treatment Options for DME

1.  Medication Injections

– Anti-VEGF Therapy: Drugs like Avastin, Lucentis, and Eylea can be injected into the eye to block a specific protein that causes the blood vessels to leak.

– Steroid Implants: For some people, steroid medications can help. These are implanted into the eye and slowly release medication over time.

2.Laser Therapy

Focal/grid laser therapy can be used to slow the leakage of fluid, treating the swollen areas of the retina.

3.  Surgery

A surgical procedure known as a “vitrectomy” may be recommended in severe cases.

Living with DME

Managing DME is a long-term commitment that will likely involve regular visits to an eye specialist. Lifestyle changes like maintaining a balanced diet and keeping your blood sugar levels in check are vital. Consult your healthcare team for a tailored treatment plan.

Conclusion

Diabetic Macular Edema is a significant concern for people with diabetes. Understanding the risk factors and available treatment options can make a huge difference in your quality of life. Regular eye check-ups and early diagnosis are crucial for effective management.

If you have further questions or need more in-depth information, consult your healthcare provider for personalized advice.

We hope this guide has been helpful in explaining Diabetic Macular Edema in a straightforward manner. Thank you for taking the time to read and educate yourself about this important eye condition.

Disclaimer: This information is intended for general educational purposes and should not be considered as medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment.

The post Diabetic Macular Edema- Risk Factors and Treatment Options appeared first on Dr Rehman Siddiqui.

What is Anti-VEGF?

Vascular Endothelial Growth Factor (VEGF) is a protein that promotes the formation of new blood vessels. While generally beneficial for wound healing and in the formation of the circulatory system, excessive VEGF production can be detrimental in certain ocular conditions. Anti-VEGF injections inhibit the action of VEGF, thereby curbing abnormal blood vessel growth and fluid leakage in the eye, which are often the underlying causes of vision loss in diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion.

Anti-VEGF injection

Indications for Anti-VEGF Therapy

1. Age-Related Macular Degeneration (AMD)

Wet AMD: Characterized by the abnormal growth of blood vessels in the macula, the central part of the retina. These vessels tend to leak fluid, leading to scarring and a rapid loss of central vision.

2. Diabetic Retinopathy

a. Proliferative diabetic retinopathy (PDR): Late-stage diabetic eye disease characterized by the growth of fragile blood vessels that can bleed into the vitreous, causing severe vision impairment.

b. Diabetic macular edema (DME): A complication of diabetic retinopathy, DME involves the swelling of the macula due to fluid accumulation.

3. Retinal Vein Occlusion: A blockage in the retinal vein leads to swelling and hemorrhages, causing vision loss. Anti-VEGF treatment may minimize swelling and improve vision.

Other Conditions:

Macular edema secondary to uveitis

Choroidal neovascularization not related to AMD

Rubeosis secondary to any cause

Procedure Details

Local Anesthesia: Topical anesthetic drops are applied to numb the eye surface.

Sterilization: The eye and surrounding areas are disinfected with brown coloured povidone iodine.

Injection: A fine needle delivers the anti-VEGF medication into the vitreous, the gel-like substance in the eye’s center.

Post-procedure Care

Prescription of antibiotic drops to prevent infection

Follow-up visits for monitoring the eye’s response to treatment

Additional injections might be necessary, depending on the disease’s progression.

Complications

Irritation and watering: Hypersensitivity to the disinfecting medication might result in redness, itching, and irritation. This usually lasts for 24-48 hours maximum.

Subconjunctival Hemorrhage: Bleeding at the injection site can occur but typically resolves without treatment in 10-14 days.

Increased Intraocular Pressure: Temporary spikes in eye pressure are common but generally resolve within a day.

Retinal Detachment: Rarely mechanical injury from the injection could lead to a detachment of the retina.

Infection: Though very rare, endophthalmitis, an infection of the internal structures of the eye, can occur. This is a serious complication. Immediate medical attention is required. Significant drop in vision associated with severe pain is usually the initial presentation. Urgent medical treatment is required.

Alternative Treatment Options

For AMD

Photodynamic Therapy (PDT): A light-activated drug is used to seal off leaking blood vessels. Rarely used today because of scarring.

Laser Coagulation: High-energy light burns and seals the abnormal vessels but is rarely used today due to high risk of scarring.

For Diabetic Retinopathy

Panretinal Photocoagulation: Laser treatment to shrink abnormal blood vessels.

Vitrectomy: Surgical removal of the vitreous gel to clear blood and scar tissue.

For Retinal Vein Occlusion

Corticosteroid Implants: Steroids can reduce macular edema but come with a higher risk of complications like cataract formation and glaucoma.

Conclusion

Anti-VEGF injections are a pivotal treatment option for several vision-threatening diseases. However, the procedure comes with its set of risks and complications that require a comprehensive discussion with your healthcare provider. Multiple treatment sessions may be necessary for optimal outcomes. Alternative therapies do exist but are generally considered less effective or riskier.

For personalized advice, consult your ophthalmologist to discuss the most suitable treatment options for your condition.

Disclaimer: This information is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition.

The post Anti-VEGF injections appeared first on Dr Rehman Siddiqui.

What is a Retinal Vein Occlusion (RVO)?

Retinal vein occlusion (RVO) is a blockage or occlusion of a vein that carries blood away from the retina of the eye. The retina is the tissue located at the back of the eye responsible for vision. When the vein is blocked, blood and fluid accumulate in the retina, leading to reduced vision or even vision loss.

What are the types of RVO?

There are two types of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

• Central retinal vein occlusion (CRVO) occurs when the main vein that drains the entire retina is blocked.
• Branch retinal vein occlusion (BRVO) occurs when one of the smaller veins branching off the main vein becomes blocked.

What are the symptoms of CRVO?

The symptoms of CRVO can vary depending on the severity and type of the occlusion. However, the common symptoms include:

• Sudden, painless vision loss or blurred vision
• Seeing floaters or dark spots in the vision
• Distorted or wavy vision
• Loss of peripheral vision
• Eye pain

How prevalent is CRVO, and who is at risk?

CRVO is a relatively uncommon condition, affecting around 1% of the general population. The risk of developing CRVO increases with age and in people with certain underlying medical conditions, including:

• High blood pressure
• Diabetes
• Glaucoma
• Atherosclerosis (narrowing of blood vessels)
• Blood clotting disorders
• Elevated cholesterol levels
• Cardiovascular disease

Other risk factors for CRVO include smoking, obesity, and a family history of the condition.

How is CRVO diagnosed?

CRVO is diagnosed through a comprehensive eye exam by an ophthalmologist or optometrist. The exam may include:

• Visual acuity test: This is a standard eye chart test to measure vision.
• Dilated eye exam: The doctor will use drops to dilate the pupil and examine the retina.
• OCT Test: This tests evaluates retinal swelling (macular edema) caused by vein occlusion. If macular edema is established on OCT test, it is an indication for treatment.
• Fluorescein angiography: This is a specialized test where a dye is injected into the arm, and photographs are taken of the retina to assess blood flow and detect blockages.

What are the treatment options for CRVO?

The treatment for CRVO depends on the severity and type of the occlusion. The aim of treatment is to reduce swelling and prevent further vision loss.

• Observation: In some cases -when there is no retinal swelling- the doctor may recommend close monitoring of the condition to see if it resolves on its own.
• Injections: Most patients with reduced vision and macular edema will need anti-VEGF injections into the eye to reduce swelling and improve blood flow.
• Medications: Medications may be prescribed to reduce swelling, including anti-inflammatory drugs, steroids, and blood thinners.
• Laser therapy: Laser therapy is a procedure where a high-intensity beam of light is used to seal leaky blood vessels and reduce swelling.

Most patients with reduced vision and macular edema will need multiple anti-VEGF injections into the eye to reduce swelling and improve vision.

Are the procedures painful?

Some treatments for CRVO, such as laser therapy and injections, may cause some discomfort. However, the doctor will usually use a local anesthetic to numb the area before the procedure to minimize any pain or discomfort.

What are the complications of CRVO treatment?

Some of the potential complications of CRVO treatment include:

• Infection
• Bleeding
• Increased eye pressure
• Cataracts
• Retinal detachment

Your doctor will discuss the potential risks and benefits of any treatment options with you before proceeding with the treatment.

What happens if CRVO is left untreated?

If CRVO is left untreated, the blockage can lead to permanent vision loss. In severe cases, the eye pressure may go up causing a painful blind eye.

Untreated CRVO may lead to a blind painful eye.

The post Central Retinal Vein Occlusion (CRVO) appeared first on Dr Rehman Siddiqui.

What is a Retinal Vein Occlusion (RVO)?

Retinal vein occlusion (RVO) is a blockage or occlusion of a vein that carries blood away from the retina of the eye. The retina is the tissue located at the back of the eye responsible for vision. When the vein is blocked, blood and fluid accumulate in the retina, leading to reduced vision or even vision loss.

What are the types of RVO?

There are two types of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

• Central retinal vein occlusion (CRVO) occurs when the main vein that drains the entire retina is blocked.
• Branch retinal vein occlusion (BRVO) occurs when one of the smaller veins branching off the main vein becomes blocked.

What are the symptoms of BRVO?

The symptoms of BRVO can vary depending on the severity and type of the occlusion. However, the common symptoms include:

• Sudden, painless vision loss or blurred vision
• Seeing floaters or dark spots in the vision
• Distorted or wavy vision
• Loss of peripheral vision
• Eye pain

How prevalent is BRVO, and who is at risk?

BRVO is a relatively common condition, affecting around 1% of the general population. The risk of developing BRVO increases with age and in people with certain underlying medical conditions, including:

• High blood pressure
• Diabetes
• Glaucoma
• Atherosclerosis (narrowing of blood vessels)
• Blood clotting disorders
• Elevated cholesterol levels
• Cardiovascular disease

Other risk factors for RVO include smoking, obesity, and a family history of the condition.

How is BRVO diagnosed?

BRVO is diagnosed through a comprehensive eye exam by an ophthalmologist or optometrist. The exam may include:

• Visual acuity test: This is a standard eye chart test to measure vision.
• Dilated eye exam: The doctor will use drops to dilate the pupil and examine the retina.
• OCT Test: This tests evaluates retinal swelling (macular edema) caused by vein occlusion. If macular edema is established on OCT test, it is an indication for treatment.
• Fluorescein angiography: This is a specialized test where a dye is injected into the arm, and photographs are taken of the retina to assess blood flow and detect blockages.

What are the treatment options for BRVO?

The treatment for BRVO depends on the severity and type of the occlusion. The aim of treatment is to reduce swelling and prevent further vision loss.

• Observation: In some cases, the doctor may recommend close monitoring of the condition to see if it resolves on its own.
• Medications: Medications may be prescribed to reduce swelling, including anti-inflammatory drugs, steroids, and blood thinners.
• Laser therapy: Laser therapy is a procedure where a high-intensity beam of light is used to seal leaky blood vessels and reduce swelling.
• Injections: Most patients with reduced vision and macular edema will need anti-VEGF injections into the eye to reduce swelling and improve blood flow.

Are the procedures painful?

Some treatments for BRVO, such as laser therapy and injections, may cause some discomfort. However, the doctor will usually use a local anesthetic to numb the area before the procedure to minimize any pain or discomfort.

What are the complications of BRVO treatment?

Some of the potential complications of BRVO treatment include:

• Infection
• Bleeding
• Increased eye pressure
• Cataracts
• Retinal detachment

Your doctor will discuss the potential risks and benefits of any treatment options with you before proceeding with the treatment.

What happens if BRVO is left untreated?

If BRVO is left untreated, the blockage can lead to permanent vision loss. In severe cases, there may be bleeding inside the eye and retinal detachment.

The post Branch Retinal Vein Occlusion (BRVO) appeared first on Dr Rehman Siddiqui.

What is Vitreomacular Traction Syndrome (VMTS)?

Vitreomacular traction is a condition that occurs when the gel-like substance in the center of the eye (vitreous) pulls on the retina, the light-sensitive layer at the back of the eye. This traction can cause the retina to become detached, leading to vision loss.

What causes Vitreomacular Traction Syndrome (VMTS)?

As we age, the vitreous shrinks. In some people, while shrinking, the vitreous may pull on the retina. The pulling of the retina leads to traction. Other factors that may increase the risk of VMTS include high myopia (nearsightedness), previous eye surgery, and trauma to the eye.

What are the symptoms of Vitreomacular Traction Syndrome (VMTS)?

The symptoms of VMTS can vary, but may include:

• Blurred vision.
• A decrease in visual acuity (sharpness of vision)
• Distorted vision (straight lines appearing wavy)
• “Double vision”

How is Vitreomacular Traction Syndrome (VMTS) diagnosed?

Your eye doctor can diagnose VMTS with a comprehensive eye exam. The doctor will examine the retina on a slit-lamp with a special lens and will also use a test called optical coherence tomography (OCT) to take detailed images of the retina and vitreous.

What are the treatment options for Vitreomacular Traction Syndrome (VMTS)?

The goal of treatment for VMTS is to release the traction on the retina and prevent vision loss. Treatment options include:

• Observation: If the traction is mild and not affecting vision, your doctor may recommend simply monitoring the condition and checking for any changes.
• Vitrectomy: This is a surgical procedure in which the vitreous is removed from the eye. The procedure is performed under local or general anesthesia and typically takes about an hour.
• Injection of a pharmacological agent: This is a non-surgical treatment in which a special drug is injected into the eye to help dissolve the vitreous gel and release the traction on the retina. The results of this treatment are variable and is not performed in Pakistan.

What can I expect after treatment for Vitreomacular Traction Syndrome (VMTS)?

The recovery time after treatment for VMTS varies, depending on the type of treatment you receive. You should expect to rest your eyes for several days after vitrectomy  and you may need to wear an eye patch or use anti-biotic drops. Your doctor will provide you with specific instructions for care after your treatment.

What are the potential complications of Vitreomacular Traction Syndrome (VMTS) treatment?

As with any medical procedure, there is a risk of complications with treatment for VMTS. Potential complications of a vitrectomy procedure include infection, bleeding, retinal detachment, cataract formation, and vision loss. Follow up OCT scans are usually done to evaluate treatment success. Most patients do very well indeed after treatment for VMTS.

The post Vitreo-Macular Traction Syndrome (VMTS) appeared first on Dr Rehman Siddiqui.